Developing potential biomarkers through bedside-to-bench translation

A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential

Prostate cancer (PCA) is a major health concern in current times. Ever since prostate specific antigen (PSA) was introduced in clinical practice almost three decades ago, the diagnosis and management of PCA have been revolutionized. With time, concerns arose as to the inherent shortcomings of this biomarker and alternatives were actively sought. Over the past decade new PCA biomarkers have been...

Justice in translation: from bench to bedside in the developing world.

Prostate Cancer Biomarkers– A Bench to Bedside Perspective

Prostate cancer (PCa) is the most common non-cutaneous malignancy in men and is responsible for the second most common age-adjusted death rate due to cancer among men in the US, after lung cancer [1]. The prevalence of PCa increases with age with the chance of detecting PCa in an 80 year-old male being as high as 60% [2]. While PCa is generally considered a disease of “old age” with most men dy...

Clinical utility of asthma biomarkers: from bench to bedside

Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easi...

Dr. Herman Kabat: neuroscience in translation … from bench to bedside.